Boeing Secures Multi-Billion Dollar Defense Contracts for F-15IA Jets and E-4B Aircraft Support 
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
BETHLEHEM, Pa., Feb. 24, 2017 -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point of care diagnostic tests and specimen collection devices, today announced that Roger L. Pringle will be retiring as a member of the Company’s Board of Directors, effective May 16, 2017. Mr. Pringle is the Company’s longest tenured Director, having served on the Board since September 2000. Prior to that, Mr. Pringle served as Chairman of the Board and Director of one of the Company’s predecessors, Epitope, Inc. Mr. Pringle has also served as a member of both the Compensation and Audit Committees and previously as Chairman of the Compensation Committee.
“On behalf of the Company and my fellow Directors, I would like to express my deepest appreciation to Roger for his dedicated service to the Company and the Board of Directors,” said Dr. Stephen Tang, Chairman of OraSure’s Board of Directors. “During Roger’s tenure, there have been many significant changes at OraSure and the Company has grown substantially. His steadfast commitment and leadership have contributed to our success over these many years. Roger will be greatly missed and we wish him and his family nothing but good health and success for the future.”
About OraSure Technologies
OraSure Technologies is a leader in the development, manufacture and distribution of point of care diagnostic and collection devices and other technologies designed to detect or diagnose critical medical conditions. Its first-to-market, innovative products include rapid tests for the detection of antibodies to HIV and HCV on the OraQuick® platform, oral fluid sample collection, stabilization and preparation products for molecular diagnostic applications, and oral fluid laboratory tests for detecting various drugs of abuse. OraSure's portfolio of products is sold globally to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, research and academic institutions, distributors, government agencies, physicians' offices, commercial and industrial entities and consumers. The Company's products enable healthcare providers to deliver critical information to patients, empowering them to make decisions to improve and protect their health.
For more information on OraSure Technologies, please visit www.orasure.com.
Company contact: Ronald H. Spair Chief Financial Officer 610-882-1820 [email protected] www.orasure.com
